Return to search

Spaltudaq Raises $29 Million

Spaltudaq Corp., a Seattle-based biotech company focused on therapeutic human monoclonal antibodies, has raised $29 million in Series B funding. Arch Venture Partners, Canaan Partners and Healthcare Ventures co-led the deal, and were joined by Amgen Ventures, MPM Capital, and Alexandria Equities. www.spaltudaq.com